European Commission approves cemiplimab (Libtayo®) for the treatment of adults with advanced basal cell carcinoma

Approval of the PD-1 inhibitor for use in those who have progressed on or are intolerant to a hedgehog pathway inhibitor was based on data from a study (n=119) in which it was associated with an objective response rate of 32% in locally advanced and 29% in metastatic disease.

Biospace Inc.